Nebula Genomics is a human genome sequencing and health big data company on a mission to usher in the era of genomic sequencing by building a large and trusted genomic and health data marketplace for consumers, researchers and the medical community. Using blockchain to ensure that consumers maintain control of their data and are compensated for its use, the Nebula marketplace will aggregate a critical mass of rich genetic information that researchers can analyze in order to accelerate drug development, streamline clinical trials, and usher in the era of truly personalized medicine. The company was founded by Harvard genomics pioneer George Church, along with Harvard researchers Dennis Grishin and Kamal Obbad. Founded in 2017, Nebula Genomics has offices in San Francisco, CA and Boston, MA and is backed by investors including Khosla Ventures, Arch Venture Partners, Fenbushi Capital, Mayfield, F-Prime Capital Partners, GreatPoint Ventures, Hemi Ventures and Mirae Asset. Free DNA Sequencing company, Nebula Genomics is building a platform that connects patients and consumers with researchers and incentivizes data sharing by ensuring equitable compensation, transparency, and security. Our platform can be used to gain data from various kinds of genetic studies. Observational studies that aim to understand associations between genetic variation and disease in large populations (e.g. UK Biobank, FinnGen). Observational studies of patients with specific medical conditions. These are typically smaller genetic studies with relatively narrow inclusion criteria.. Sequencing of clinical trial participants and return or results. Today, participants of clinical trials are often sequenced or genotyped. The generated genomic data can be used to guide the course of the ongoing clinical trial or for future studies. Nebula established a partnership with Inspire, a company with a healthcare social network of more than 1.5 million patients and caregivers, representing over 3,600+ medical conditions, such as lung cancer, idiopathic pulmonary fibrosis, and neurofibromatosis. Many of Inspire’s members are actively engaged in their health and are constantly seeking for leading-edge treatment options, and are gathering and sharing information through the online community.